stockrowFate Therapeutics, Inc.
FATEFate Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 million, down 51.2% from fiscal 2024.
- Revenue
- +9.18%
- EPS
- +13.8%
- Free cash flow
- +8.96%
Quarter to June 2026, against a year earlier
Follow FATE
Alert me
Fate Therapeutics, Inc. (FATE) EV/Sales
As of 6 November 2026, Fate Therapeutics, Inc. (FATE) trades at a EV/Sales of 14.0×. Over the past ten years it has ranged from −11.7× (March 2025) to 453× (December 2020); the current reading is higher than 41% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −9.6× | — |
| FY2024 | −5.0× | — |
| FY2023 | 1.1× | (81.09%) |
| FY2022 | 5.9× | (93.30%) |
| FY2021 | 88.7× | (60.37%) |
| FY2020 | 224× | 110.22% |
| FY2019 | 106× | (5.70%) |
| FY2018 | 113× | 149.15% |
| FY2017 | 45.3× | 4,891.32% |
| FY2016 | 0.9× | (94.39%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 30.0× | — |
| Mar 2026 | −1.2× | — |
| Dec 2025 | −9.6× | — |
| Sep 2025 | −5.9× | — |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | 0.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.1× |
| ACIU AC Immune compare | 9.1× |
| FATE Fate Therapeutics, Inc. | 14.0× |
| KRRO Korro Bio, Inc. compare | 25.5× |
| IMRX Immuneering Corporation compare | 293× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)